Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 4/20 | 0.37 |
| ▸ | SUZ12 | Q15022 | 3/20 | 0.37 |
| ▸ | EZH2 | Q15910 | 3/20 | 0.37 |
| ▸ | HTR6 | P50406 | 2/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2476690 | 0.99 | EED (0.36) | EEDSUZ12EZH2HTR6PRMT5 | |
| SCHEMBL1581025 | 0.89 | ALOX5AP (0.35) | EEDSUZ12EZH2ALOX5APFEN1 | |
| Hydrochloric Acid SCHEMBL5002930 | 0.89 | ALOX5AP (0.34) | EEDSUZ12EZH2HTR6ALOX5AP | |
| SCHEMBL1580608 | 0.87 | HTR6 (0.41) | EEDSUZ12EZH2HTR6ALDH1A1 | |
| SCHEMBL1580625 | 0.86 | PPME1 (0.40) | EEDSUZ12EZH2HTR6PRMT5 | |
| Hydrochloric Acid SCHEMBL2409367 | 0.85 | PPME1 (0.39) | EEDSUZ12EZH2HTR6PRMT5 | |
| SCHEMBL1580992 | 0.85 | MET (0.36) | HTR6PRMT5WDR77PTGDR2 | |
| Hydrochloric Acid SCHEMBL2409973 | 0.84 | MET (0.36) | HTR6PRMT5WDR77PTGDR2 | |
| SCHEMBL4998955 | 0.83 | USP19 (0.34) | EEDSUZ12EZH2PTGDR2ALDH1A1 | |
| SCHEMBL4998963 | 0.83 | PTGDR2 (0.34) | EEDSUZ12EZH2PTGDR2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9186411-B2 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20130261156-A1 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-03 | — | — | US | disclosed |
| EP-2564833-A1 | Photostabilized pharmaceutical composition | Takeda Pharmaceutical Company Limited (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20110124687-A1 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| EP-2309985-A2 | PHARMACEUTICAL COMPOSITION | Takeda Pharmaceutical Company Limited (JP) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010013823-A2 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124687-A1 | PHARMACEUTICAL COMPOSITION | CYP2C19, MLST8, CYP3A43 | EED 928/4885SUZ12 194/4885EZH2 1963/4885 |
| US-20130261156-A1 | PHARMACEUTICAL COMPOSITION | CYP2C19, MLST8, CYP3A43 | EED 928/4885SUZ12 194/4885EZH2 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.